… The patient with a liver function study abnormality who received … Dose-escalating and
pharmacological study of oxaliplatin in … Cancer Institute Organ Dysfunction Working Group Study. J …

… After 2 weeks, her liver function tests and total bilirubin levels showed improvement and
modified regimen of FOLFOX6 with oxaliplatin 85 mg/m 2 and continuous infusion of 5-FU 2400 …

… of liver function in patients with different cancers. The severity of … the organ dysfunction,
pharmacokinetics and pharmacology … such as the NCI Organ Dysfunction Working Group (NCI-…

… Organ Dysfunction Working Group's hepatic impairment categorization and two drug-induced
liver … scores of hepatic function, such as the Model for End-Stage Liver Disease or Child–…

… The patient died shortly thereafter from end organ failure. … JL: Dose escalating and
pharmacological study of oxaliplatin in … Cancer Institute Organ Dysfunction Working Group study. J …

… 130 mg/m 2 oxaliplatin in the cohort with severe liver dysfunction. … However, formal phase I
studies on PKs and dosing … those with hepatobiliary cancer and impaired liver function are still …

… 130 mg/m2 is still below the maximally-tolerated level in patients with abnormal liver function
[41]. Total body … national cancer institute organ dysfunction working group. Semin. Oncol. …

… At baseline, the patient had normal hepatic function and no signs of ascites or pleural effusion.
The laboratory findings on admission were as follows: white blood cell count 4250/mm 3 , …

… For the elderly, there is a need to provide the best cancer treatment possible, whether … of
cancer treatment that may be exacerbated by poor renal function or general functional status. …

… of ultrafilterable oxaliplatin is decreased in patients with mild-to-moderate renal impairment
(… Importantly, no deterioration of renal function in these patients has been reported. Only 2% …